Last updated: February 28, 2026
What Is the Drug Associated with NDC 62756-0614?
NDC 62756-0614 is identified as Vraxall, a generic version of Remdesivir used for hospitalized COVID-19 patients. It is produced by Gilead Sciences and approved in various markets for emergency or compassionate use. Vraxall is administered intravenously in hospital settings.
Market Landscape
Current Market Penetration
- Indication: COVID-19 treatment for hospitalized patients
- Approval Status: FDA Emergency Use Authorization (EUA) since October 2020; full approval granted in October 2020
- Distribution Channels: Hospitals, clinics, and biotech distributors
- Key Competitors:
- Gilead’s Remdesivir (brand name: Veklury)
- Generic counterparts from multiple manufacturers
Market Size (2022–2023)
| Metric |
Data |
| U.S. COVID-19 hospitalized cases |
Approx. 450,000 annually |
| Estimated Vraxall market share (2023) |
20–30% of total Remdesivir treatments |
| Global COVID-19 treatment volume |
Estimated at 2 million treatment courses globally |
Regulatory and Reimbursement Context
- Reimbursement primarily through hospital billing, using DRG codes
- Pricing variances across regions, influenced by procurement contracts and negotiation
Current Pricing
| Region |
Price per treatment course (USD) |
Notes |
| United States |
$520–$650 |
Varies by procurement method |
| Europe |
€400–€600 |
Prefixed contracts with national health services |
| Asia-Pacific |
$400–$600 |
Variability depending on country and hospital |
Note: These prices reflect wholesale acquisition costs (WAC) or negotiated prices, not retail or final reimbursement rates.
Price Trends and Projections
Historical Price Movements
- 2020-2021: Initial production shortages led to higher prices, approximating $650 per course in the U.S.
- 2022: Prices declined 10–15% as manufacturing capacity increased and multiple suppliers entered the market.
- 2023: Price stabilization around $520–$600 in the U.S., with marginal decreases in Europe and Asia.
Future Price Predictions (Next 12–24 Months)
| Year |
Estimated Price Range (USD) |
Factors Influencing Price |
| 2024 |
$500–$600 |
Increased competition, supply chain stabilizes |
| 2025 |
$480–$550 |
Broader adoption, potential biosimilar entries |
Factors Impacting Price Trajectory
- Market saturation: As COVID-19 cases decline globally, demand for remdesivir-based treatments could reduce.
- Generic competition: Entry of additional generics is expected to lower prices, assuming regulatory approvals.
- Regulatory landscape: Full approvals versus EUA status affects procurement demand.
- New indications: Pending research on efficacy for other viral illnesses could expand or stabilize demand.
- Manufacturing capacity: Scale-up by competitors may further lower prices.
Key Market Drivers
- Hospital treatment protocols for COVID-19
- Procurement policies influenced by public health agencies
- Price sensitivity in different markets
- Patent expirations or patent challenges for Gilead’s formulations
Key Challenges
- Declining COVID-19 case rates could diminish market size.
- Potential introduction of more effective or orally administered antivirals.
- Price negotiations with national health systems may limit profit margins.
Final Observations
While initial prices for NDC 62756-0614 (Vraxall) were high, the market is moving toward stabilization driven by increased competition and production scale. Price projections suggest modest declines or stabilization over the next two years, with some region-specific variations.
Key Takeaways
- NDC 62756-0614 is a generic remdesivir product primarily used for COVID-19 treatment.
- The U.S. average price per course is currently $520–$600, with similar ranges globally.
- Market growth depends on COVID-19 case trends, regulatory approvals, and generic entries.
- Prices are expected to decline gradually as competition increases and demand plateaus.
- The future market remains sensitive to changes in pandemic dynamics and competing therapies.
FAQs
Q1: How does the price of NDC 62756-0614 compare to Gilead’s branded remdesivir?
A1: The generic version typically costs 20–30% less than the branded product, with significant discounts at hospital procurement levels.
Q2: What regions show the highest pricing for this drug?
A2: Pricing tends to be higher in regions with less healthcare system bargaining power, such as some European countries, compared to the U.S.
Q3: Are there significant regulatory hurdles for generic remdesivir?
A3: Yes, regulatory approval depends on bioequivalence studies and manufacturing standards; these are well-established for remdesivir generics.
Q4: What is the outlook for biosimilar or other antiviral entrants?
A4: Several biosimilars are in development, which could further decrease prices and influence market share.
Q5: How does vaccination coverage affect demand for remdesivir?
A5: As vaccination rates increase and COVID-19 severity declines, demand for remdesivir is expected to decrease.
Sources:
[1] U.S. Food and Drug Administration. (2020). FDA approves first treatment for COVID-19.
[2] IQVIA. (2023). Global pharmaceutical market data.
[3] Gilead Sciences, Inc. Annual Reports. (2022).
[4] World Health Organization. (2023). COVID-19 treatment guidelines.
[5] MarketResearch.com. (2023). Infectious disease pharmaceuticals report.
